{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "TMO",
  "name": "Thermo Fisher Scientific, Inc.",
  "url": "https://frontierpicks.com/dossiers/TMO/",
  "json_url": "https://frontierpicks.com/dossiers/TMO.json",
  "status": "WATCHLIST",
  "current_conviction": "MEDIUM",
  "archetype": {
    "code": "a2",
    "n": 2
  },
  "current_thesis": "Thermo Fisher Scientific's 6% third-quarter organic growth, raised 2026 outlook and $5 billion buyback give the shares a modest edge over the S&P 500. The late-January 2027 report and first 2027 guidance decide whether that growth holds.",
  "invalidation_trigger": "A daily close below $650, under the 50-day moving average, which would give back much of the rally that followed the 2026-10-21 report. Fourth-quarter organic growth below the 4% guidance, or initial 2027 organic growth guidance below the 2026 rate, would also break the case.",
  "catalyst_date": null,
  "portfolio": null,
  "pick": null,
  "themes": [
    "medtech-diagnostics"
  ],
  "tags": [],
  "sources": [],
  "caveats": [],
  "source_links": [
    {
      "title": "THERMO FISHER SCIENTIFIC INC. - Form 8-K - FY2026",
      "url": "https://www.sec.gov/Archives/edgar/data/0000097745/000009774526000173/q32026earnings8kex99_1.htm",
      "date": null
    },
    {
      "title": "Stockhouse",
      "url": "https://stockhouse.com/news/press-releases/2026/11/05/thermo-fisher-scientific-authorizes-5-billion-of-share-repurchases",
      "date": "2026-11-05"
    },
    {
      "title": "Thermo Fisher Scientific Authorizes $5 Billion Share Buyback after Upbeat Earnings",
      "url": "https://www.benzinga.com/news/health-care/26/11/62984709/thermo-fisher-scientific-authorizes-5-billion-share-buyback-after-upbeat-earnings",
      "date": null
    },
    {
      "title": "Pharmaceutical Technology",
      "url": "https://www.pharmaceutical-technology.com/analyst-comment/jpm26-thermofisher-very-positive-on-strategic-ma-as-deals-expand-capabilities/",
      "date": null
    },
    {
      "title": "Thermo Fisher Scientific Continues Semiconductor Lab-to-Fab Innovation with Multiple Installations of Optis™ FIB-SEM",
      "url": "https://www.biospace.com/press-releases/thermo-fisher-scientific-continues-semiconductor-lab-to-fab-innovation-with-multiple-installations-of-optis-fib-sem",
      "date": "2026-11-10"
    },
    {
      "title": "Stock Market Today, Nov. 9: Markets Rally as Semiconductor Gains Lift Nasdaq",
      "url": "https://finance.yahoo.com/markets/stocks/articles/stock-market-today-nov-9-222339218.html",
      "date": null
    }
  ],
  "evidence": [
    {
      "claim": "Third-quarter 2026 revenue was $12.14 billion, up 9%, with 6% organic growth; adjusted EPS was $6.68, up 15%; adjusted operating margin was 24.5%, up from 23.3% a year earlier.",
      "source": "Thermo Fisher Q3 2026 8-K, Exhibit 99.1",
      "as_of": "2026-10-21"
    },
    {
      "claim": "2026 guidance was raised to revenue of $47.7-$48.2 billion and adjusted EPS of $25.13-$25.43; fourth-quarter organic growth guidance stayed at 4%.",
      "source": "Q3 2026 earnings call",
      "as_of": "2026-10-21"
    },
    {
      "claim": "Management attributed $0.15 of EPS above prior guidance to tariff refunds, $0.08 to operations and $0.03 to currency.",
      "source": "Q3 2026 earnings call",
      "as_of": "2026-10-21"
    },
    {
      "claim": "The board authorized up to $5 billion of share repurchases with no expiration date, replacing an authorization with $1 billion remaining.",
      "source": "Thermo Fisher press release",
      "as_of": "2026-11-05"
    },
    {
      "claim": "The company is issuing 800 million Swiss francs of bonds in four tranches maturing in 3 to 12 years.",
      "source": "Thermo Fisher company announcement",
      "as_of": "2026-11-02"
    },
    {
      "claim": "Chief HR Officer Lisa P. Britt sold 2,831 shares in the open market at $706.45.",
      "source": "SEC Form 4 filed 2026-10-30",
      "as_of": "2026-10-28"
    },
    {
      "claim": "Argus Research maintained a Buy rating and raised its price target to $780.",
      "source": "Argus Research note via Benzinga",
      "as_of": "2026-10-30"
    },
    {
      "claim": "At the J.P. Morgan Healthcare Conference, CEO Marc Casper framed 2026 and 2027 organic growth at 3% to 6%, with 7% or more from 2028.",
      "source": "Pharmaceutical Technology coverage of JPM26",
      "as_of": "2026-01-13"
    }
  ],
  "view_changes": [],
  "frame": null,
  "filed_numbers": {
    "as_of": "2026-11-13",
    "sector": "Technology",
    "financials": {
      "status": "ok",
      "reason": null,
      "close_date": "2026-11-13",
      "latest_quarter": "2026-09-26",
      "figures": {
        "revenue": {
          "status": "ok",
          "quarters": [
            {
              "end": "2026-09-26",
              "filed": "2026-10-30",
              "restated": null,
              "value_musd": 12137,
              "yoy_pct": 9.1
            },
            {
              "end": "2026-06-27",
              "filed": "2026-07-31",
              "restated": null,
              "value_musd": 11994,
              "yoy_pct": 10.5
            },
            {
              "end": "2026-03-28",
              "filed": "2026-05-01",
              "restated": null,
              "value_musd": 11005,
              "yoy_pct": 6.2
            },
            {
              "end": "2025-12-31",
              "filed": "2026-02-26",
              "restated": null,
              "value_musd": 12215,
              "yoy_pct": 7.2
            },
            {
              "end": "2025-09-27",
              "filed": "2025-10-31",
              "restated": null,
              "value_musd": 11122,
              "yoy_pct": 4.9
            },
            {
              "end": "2025-06-28",
              "filed": "2025-08-01",
              "restated": null,
              "value_musd": 10855,
              "yoy_pct": 3
            }
          ]
        },
        "gross_margin": {
          "status": "not reported"
        },
        "operating_margin": {
          "status": "ok",
          "quarters": [
            {
              "end": "2026-09-26",
              "filed": "2026-10-30",
              "restated": null,
              "pct": 18.6
            },
            {
              "end": "2026-06-27",
              "filed": "2026-07-31",
              "restated": null,
              "pct": 17.4
            },
            {
              "end": "2026-03-28",
              "filed": "2026-05-01",
              "restated": null,
              "pct": 16.9
            },
            {
              "end": "2025-12-31",
              "filed": "2026-02-26",
              "restated": null,
              "pct": 18.5
            },
            {
              "end": "2025-09-27",
              "filed": "2025-10-31",
              "restated": null,
              "pct": 17.5
            },
            {
              "end": "2025-06-28",
              "filed": "2025-08-01",
              "restated": null,
              "pct": 16.9
            }
          ]
        },
        "pretax_income": {
          "status": "ok",
          "end": "2026-09-26",
          "filed": "2026-10-30",
          "value_musd": 2088
        },
        "net_income": {
          "status": "ok",
          "end": "2026-09-26",
          "filed": "2026-10-30",
          "four_quarters_end": "2026-09-26",
          "value_musd": 1721,
          "four_quarters_musd": 7072
        },
        "operating_cash_flow": {
          "status": "ok",
          "end": "2026-09-26",
          "filed": "2026-10-30",
          "first_end": "2025-12-31",
          "value_musd": 9324
        },
        "capital_spending": {
          "status": "ok",
          "end": "2026-09-26",
          "filed": "2026-10-30",
          "first_end": "2025-12-31",
          "value_musd": 1728
        },
        "free_cash_flow": {
          "status": "ok",
          "end": "2026-09-26",
          "filed": "2026-10-30",
          "first_end": "2025-12-31",
          "value_musd": 7596
        },
        "diluted_share_change": {
          "status": "ok",
          "end": "2026-09-26",
          "filed": "2026-10-30",
          "base_end": "2025-09-27",
          "pct": -1.9
        },
        "cash": {
          "status": "ok",
          "end": "2026-09-26",
          "filed": "2026-10-30",
          "value_musd": 6061
        },
        "debt": {
          "status": "ok",
          "end": "2026-09-26",
          "filed": "2026-10-30",
          "value_musd": 41370,
          "composition": "non-current long-term debt and finance leases plus current debt"
        },
        "net_cash": {
          "status": "ok",
          "end": "2026-09-26",
          "filed": "2026-10-30",
          "value_musd": -35309
        },
        "deferred_revenue": {
          "status": "ok",
          "end": "2026-09-26",
          "filed": "2026-10-30",
          "value_musd": 4025,
          "yoy_pct": 0.3
        },
        "backlog": {
          "status": "ok",
          "end": "2026-09-26",
          "filed": "2026-10-30",
          "value_musd": 29870,
          "yoy_pct": 12.9
        },
        "receivables": {
          "status": "ok",
          "end": "2026-09-26",
          "filed": "2026-10-30",
          "value_musd": 9625
        },
        "inventory": {
          "status": "ok",
          "end": "2026-09-26",
          "filed": "2026-10-30",
          "value_musd": 5643
        },
        "equity": {
          "status": "ok",
          "end": "2026-09-26",
          "filed": "2026-10-30",
          "value_musd": 54761
        },
        "market_value": {
          "status": "ok",
          "close_date": "2026-11-13",
          "basis_end": "2026-09-26",
          "basis_filed": "2026-10-30",
          "value_musd": 259442.6
        },
        "enterprise_value": {
          "status": "ok",
          "close_date": "2026-11-13",
          "basis_end": "2026-09-26",
          "basis_filed": "2026-10-30",
          "value_musd": 294751.6
        },
        "ev_sales": {
          "status": "ok",
          "close_date": "2026-11-13",
          "basis_end": "2026-09-26",
          "basis_filed": "2026-10-30",
          "multiple": 6.2
        },
        "ev_ebit": {
          "status": "ok",
          "close_date": "2026-11-13",
          "basis_end": "2026-09-26",
          "basis_filed": "2026-10-30",
          "multiple": 34.8
        },
        "pe": {
          "status": "ok",
          "close_date": "2026-11-13",
          "basis_end": "2026-09-26",
          "basis_filed": "2026-10-30",
          "multiple": 36.7
        },
        "pb": {
          "status": "ok",
          "close_date": "2026-11-13",
          "basis_end": "2026-09-26",
          "basis_filed": "2026-10-30",
          "multiple": 4.7
        },
        "fcf_yield": {
          "status": "ok",
          "close_date": "2026-11-13",
          "basis_end": "2026-09-26",
          "basis_filed": "2026-10-30",
          "pct": 2.9
        }
      }
    },
    "short_interest": {
      "status": "ok",
      "settlement": "2026-10-15",
      "published": "2026-10-26",
      "short_pct_of_outstanding": 1.32,
      "days_to_cover": 2.1,
      "change_pct": -9.6
    },
    "insiders": {
      "status": "ok",
      "as_of": "2026-11-15",
      "windows": [
        {
          "days": 90,
          "status": "ok",
          "from": "2026-08-18",
          "bought_usd": 0,
          "sold_usd": 24287547.05,
          "bought_unpriced": 0,
          "sold_unpriced": 0
        },
        {
          "days": 365,
          "status": "ok",
          "from": "2025-11-16",
          "bought_usd": 0,
          "sold_usd": 135039900.37,
          "bought_unpriced": 0,
          "sold_unpriced": 0
        }
      ]
    }
  },
  "body_markdown": "## Current Thesis\nThermo Fisher Scientific's case rests on biopharma services growth that produced a third-quarter beat and a raised 2026 outlook, backed by a $5 billion buyback authorized on 2026-11-05. The rating is Medium because those results support modest outperformance, while a 4% fourth-quarter organic growth guide caps the room for upside. The fourth-quarter report and first 2027 guidance, expected around 2027-01-28, settle whether growth holds.\n\nOn 2026-10-21 the company reported third-quarter revenue of $12.14 billion, up 9%, with 6% organic growth. Organic growth excludes acquisitions, divestitures and currency. Adjusted earnings per share (EPS) were $6.68, up 15%. Management raised 2026 guidance to revenue of $47.7–$48.2 billion and adjusted EPS of $25.13–$25.43, and kept fourth-quarter organic growth guidance at 4%. The 10-Q filed on 2026-10-30 confirms quarterly revenue of $12.14 billion against $11.12 billion a year earlier.\n\nThe shares closed at $699.44 on 2026-11-12, down from $717.71 the session before. Company news carried no company-specific announcement for that session. The price already reflects the post-earnings rerating: the shares are up 19.0% over three months and sit 3.9% below the quoted 52-week high of $727.56 set on 2026-11-11.\n\n## Bull Case\n- **Buyback capacity is back to $5 billion.** The board authorized up to $5 billion of repurchases on 2026-11-05, with no expiration date, replacing an authorization with $1 billion remaining. The company repurchased $4.0 billion of stock in the first nine months of 2026, according to its 2026-10-21 8-K.\n- **Biopharma services is the growth engine.** Laboratory Products and Biopharma Services revenue was $6,863 million in the third quarter of 2026, the largest of four segments, according to the 8-K. Chief Financial Officer Jim Meyer said on the 2026-10-21 call that second-half organic growth guidance rose to 5% from 4%.\n- **Margins and cash flow improved together.** Adjusted operating margin reached 24.5% in the third quarter, up from 23.3% a year earlier. Year-to-date free cash flow was $4,618 million against $3,319 million a year earlier, and full-year guidance rose to $7.0–$7.5 billion on 2026-10-21.\n- **Clario adds earnings and a data business.** The $8.875 billion cash purchase of Clario, which supplies endpoint data for clinical trials, closed on 2026-03-24. The company expects it to add $0.45 of adjusted EPS in the first year after closing.\n- **The latest broker target sits above the shares.** Argus Research kept its Buy rating and raised its target to $780 on 2026-10-30, according to Benzinga, above the 2026-11-12 close of $699.44.\n\n## Bear Case\n- **Fourth-quarter outlook stays at 4%.** Management kept fourth-quarter organic growth guidance at 4% on 2026-10-21, below the third quarter's 6%. The CFO said much of the pharma services strength fell in the third quarter because of the timing of customer activity.\n- **Part of the earnings beat was one-off.** On the 2026-10-21 call, management attributed $0.15 of EPS outperformance against prior guidance to tariff refunds, against $0.08 from operations and $0.03 from currency.\n- **The bar for 2027 is modest.** At the J.P. Morgan Healthcare Conference on 2026-01-13, Chief Executive Marc Casper framed organic growth of 3% to 6% for 2026 and 2027, with 7% or more from 2028, according to Pharmaceutical Technology's coverage. A 2027 guide near the low end would sit poorly with shares near a 52-week high.\n- **Buybacks lean partly on new debt.** The company announced an 800 million Swiss franc bond issue in four tranches of 3 to 12 years on 2026-11-02, after paying $8.875 billion in cash for Clario in March.\n- **Insiders sold into strength.** Chief Human Resources Officer Lisa Britt sold 2,831 shares in the open market at $706.45 on 2026-10-28, her Form 4 shows. President and Chief Operating Officer Gianluca Pettiti sold 4,133 shares at $614.38 on 2026-08-31 under a Rule 10b5-1 trading plan. Executive Vice President Michael Shafer will retire at the end of 2026, the company said on 2026-10-30.\n\n## Setup & Price Structure\nThe 2026-11-12 close of $699.44 is below the highest close of the past year, $721.63 on 2026-11-09, and the quoted intraday 52-week high of $727.56 on 2026-11-11. The 52-week closing low was $438.34 on 2026-05-15, so the shares have recovered most of a year-long range in six months.\n\nAs of 2026-11-12, the 50-day moving average stood at $668.92 and the 200-day moving average at $554.21, both below the last close. The 50-day average is the nearest reference below the price. A move back through it would show the post-earnings rerating giving way. The three-month gain of 19.0% runs from a $588.29 close on 2026-08-14, before the 2026-10-21 report.\n\nThe 2026-11-12 decline gave back the gains of the two prior sessions. No dated company event accompanies it, so it reads as a pause near the high rather than a change in the business case.\n\n## Catalyst Calendar\n\n- **~2027-01-12 (est.):** J.P. Morgan Healthcare Conference presentation. Management often gives early comments on the coming year here, ahead of formal 2027 guidance.\n- **~2027-01-28 (est.):** Fourth-quarter 2026 report and first 2027 guidance. Shows whether the 4% fourth-quarter organic outlook was conservative and where 2027 growth guidance lands within the 3%-6% framework set in January 2026.\n\n## What Would Change Our Mind\n\nA daily close below $650, under the 50-day moving average, which would give back much of the rally that followed the 2026-10-21 report. Fourth-quarter organic growth below the 4% guidance, or initial 2027 organic growth guidance below the 2026 rate, would also break the case.\n\nThe risks this note tracks, each with what would confirm it:\n\n- Third-quarter pharma services strength reflected customer timing that does not repeat. Confirmed by: Fourth-quarter organic growth at or below the 4% guidance, with management citing lower biopharma services activity.\n- 2027 guidance resets growth lower after a strong 2026. Confirmed by: Initial 2027 organic growth guidance below the 2026 rate, or near the low end of the 3%-6% framework, at the late-January report.\n- Earnings quality is weaker than the headline beat suggests. Confirmed by: Further EPS outperformance driven mainly by one-off items such as tariff refunds rather than operations.\n- The share price runs ahead of broker targets as post-earnings raises fade. Confirmed by: New sell-side targets set below the 2026-11-12 close of $699.44, or target cuts outnumbering raises before the January report.\n- Debt-funded buybacks raise leverage after the Clario purchase. Confirmed by: Further bond issuance or a credit-rating outlook change tied to share repurchases.\n- Insider selling broadens as the shares sit near their high. Confirmed by: Further open-market sales on SEC Form 4 by senior officers outside Rule 10b5-1 plans.\n\n## Correlation Notes\nThermo Fisher's growth is tied to biopharma research and manufacturing spending, through its biopharma services segment and Clario's clinical-trial data business. Shifts in drug-company research budgets or biotech funding would likely move it alongside other life-science tools suppliers. The shares also track the broad market: the 2026-11-09 gain came on a day the S&P 500 rose 2.35% in a rally led by semiconductors, Yahoo Finance reported. Installations of the Optis electron microscope at unnamed chipmakers, announced on 2026-11-10, give the company a minor link to chip-equipment spending, small next to its biopharma exposure.",
  "first_seen": "2026-11-10",
  "last_analyzed": "2026-11-12T23:33:04+00:00",
  "last_synthesized": "2026-11-12",
  "date_modified": "2026-11-12",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}